Medications for the treatment of cocaine addiction: Focus on glutamatergic compounds

Cocaine Abuse: Pharmacology, Treatment and Relapse Prevention

Volumn , Issue , 2012, Pages 115-130

  Nemirovsky, Natali E ^a   Olive, M Foster ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873655127     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (120)

1. United Nations Office on Drugs and Crime. World Drug Report, 2009.
2. Substance Abuse and Mental Health Services Administration. Results from the 2008 National Survey on Drug Use and Health: National Findings. Office of Applied Studies, Rockville, MD, 2009.
3. Kalivas, PW, O'Brien, C. Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacol. Rev., 2008, 33, 166-80.
4. http://neuroscientificallychallenged.blogspot.com/2008/08/cocaine-and-glutamate-part-two.html.
5. Uys, JD, Reissner, KJ. Glutamatergic neuroplasticity in cocaine addiction. Prog. Mol. Biol. Transl. Sci., 2011, 98, 367-400.
6. Wolf, ME. The Bermuda Triangle of cocaine-induced neuroadaptations. Trends Neurosci., 2010, 33, 391-8.
7. Kauer, JA, Malenka, RC. Synaptic plasticity and addiction. Nat. Rev. Neurosci., 2007, 8, 844-858.
8. Thomas, MJ, Kalivas, PW, Shaham, Y. Neuroplasticity in the mesolimbic dopamine system and cocaine addiction. Br. J. Pharmacol., 2008, 154, 327-42.
9. Di Chiara, G, Bassareo, V. Reward system and addiction: what dopamine does and doesn't do. Curr. Opin. Pharmacol., 2007, 7, 69-76.
10. Bowers, MS, Chen, BT, Bonci, A. AMPA receptor synaptic plasticity induced by psychostimulants: the past, present, and therapeutic future. Neuron, 2010, 67, 11-24.
11. Kalivas, PW, Lalumiere, RT, Knackstedt, L, Shen, H. Glutamate transmission in addiction. Neuropharmacology, 2009, 56 (Suppl), 169-173.
12. Olive, MF. Cognitive effects of Group I metabotropic glutamate receptor ligands in the context of drug addiction. Eur. J. Pharmacol., 2010, 639, 47-58.
13. Olive, MF. Metabotropic glutamate receptor ligands as potential therapeutics for drug addiction. Curr. Drug Abuse Rev., 2009, 2, 83-98.
14. Gass, JT, Olive, MF. Glutamatergic substrates of drug addiction and alcoholism. Biochem. Pharmacol., 2008, 75, 218-265.
15. Tzschentke, TM, Schmidt, WJ. Glutamatergic mechanisms in addiction. Mol. Psychiatry, 2003, 8, 373-82.
16. Moussawi, K, Kalivas, PW. Group II metabotropic glutamate receptors (mGlu2/3) in drug addiction. Eur. J. Pharmacol., 2010, 639, 115-22.
17. Bird, MK, Lawrence, AJ. Group I metabotropic glutamate receptors: involvement in drug-seeking and drug-induced plasticity. Curr. Mol. Pharmacol., 2009, 2, 83-94.
18. Uys, JD, LaLumiere, RT. Glutamate: the new frontier in pharmacotherapy for cocaine addiction. CNS Neurol. Disord. Drug Targets, 2008, 7, 482-91.
19. Reissner, KJ, Kalivas, PW. Using glutamate homeostasis as a target for treating addictive disorders. Behav. Pharmacol., 2010, 21, 514-22.
20. Conn, PJ, Lindsley, CW, Jones, CK. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol. Sci., 2009, 30, 25-31.
21. Marino, MJ, Conn, PJ. Direct and indirect modulation of the N-methyl D-aspartate receptor: potential for the development of novel antipsychotic therapies. Curr. Drug Targets CNSNeurol. Disord., 2002, 1, 1-16.
22. Marino, MJ, Conn, PJ. Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors. Curr. Opin. Pharmacol., 2006, 6, 98-102.
23. McBean, GJ. Cerebral cystine uptake: a tale of two transporters. Trends Pharmacol. Sci., 2002, 23, 299-302.
24. Baker, DA, Xi, ZX, Shen, H, Swanson, CJ, Kalivas, PW. The origin and neuronal function of in vivo nonsynaptic glutamate. J. Neurosci., 2002, 22, 9134-41.
25. Melendez, RI, Vuthiganon, J, Kalivas, PW. Regulation of extracellular glutamate in the prefrontal cortex: focus on the cystine glutamate exchanger and group I metabotropic glutamate receptors. J. Pharmacol. Exp. Ther., 2005, 314, 139-47.
26. Baker, DA, McFarland, K, Lake, RW, Shen, H, Tang, XC et al. Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nat. Neurosci., 2003, 6, 743-749.
27. Moran, MM, McFarland, K, Melendez, RI, Kalivas, PW, Seamans, JK. Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J. Neurosci., 2005, 25, 6389-6393.
28. Madayag, A, Lobner, D, Kau, KS, Mantsch, JR, Abdulhameed, O et al. Repeated N-acetylcysteine administration alters plasticity-dependent effects of cocaine. J. Neurosci., 2007, 27, 13968-76.
29. Kau, KS, Madayag, A, Mantsch, JR, Grier, MD, Abdulhameed, O et al. Blunted cystine-glutamate antiporter function in the nucleus accumbens promotes cocaine-induced drug seeking. Neuroscience, 2008, 155, 530-7.
30. Moussawi, K, Pacchioni, A, Moran, M, Olive, MF, Gass, JT et al. N-Acetylcysteine reverses cocaine-induced metaplasticity. Nat. Neurosci., 2009, 12, 182-9.
31. Amen, SL, Piacentine, LB, Ahmad, ME, Li, S-J, Mantsch, JR et al. Repeated N-acetylcysteine reduces cocaine seeking in rodents and craving in cocaine-dependent humans. Neuropsychopharmacology, 2011, 36, 871-8.
32. LaRowe, SD, Mardikian, P, Malcolm, R, Myrick, H, Kalivas, PW et al. Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am. J. Addict., 2006, 15, 105-110.
33. Mardikian, PN, Larowe, SD, Hedden, S, Kalivas, PW, Malcolm, RJ. An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31, 389-394.
34. LaRowe, SD, Myrick, H, Hedden, S, Mardikian, P, Saladin, M et al. Is cocaine desire reduced by N-acetylcysteine? Am. J. Psychiatry, 2007, 164, 1115-7.
35. Ballon, JS, Feifel, D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J. Clin. Psychiatry, 2006, 67, 554-66.
36. Martinez-Raga, J, Knecht, C, Cepeda, S. Modafinil: a useful medication for cocaine addiction? Review of the evidence from neuropharmacological, experimental and clinical studies. Curr. Drug Abuse Rev., 2008, 1, 213-21.
37. Andersen, ML, Kessler, E, Murnane, KS, McClung, JC, Tufik, S et al. Dopamine transporter-related effects of modafinil in rhesus monkeys. Psychopharmacology, 2010, 210, 439-48.
38. Wisor, JP, Eriksson, KS. Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil. Neuroscience, 2005, 132, 1027-34.
39. Volkow, ND, Fowler, JS, Logan, J, Alexoff, D, Zhu, W et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA, 2009, 301, 1148-54.
40. Ferraro, L, Antonelli, T, O'Connor, WT, Tanganelli, S, Rambert, F et al. The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus. Neuroreport, 1997, 8, 2883-2887.
41. Ferraro, L, Antonelli, T, Tanganelli, S, O'Connor, WT, Perez de la Mora, M et al. The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade. Neuropsychopharmacology, 1999, 20, 346-56.
42. Ferraro, L, Antonelli, T, O'Connor, WT, Tanganelli, S, Rambert, FA et al. The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: evidence for a preferential inhibition of striato-pallidal GABA transmission. Neurosci. Lett., 1998, 253, 135-8.
43. Dackis, CA, Lynch, KG, Yu, E, Samaha, FF, Kampman, KM et al. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend., 2003, 70, 29-37.
44. Malcolm, R, Swayngim, K, Donovan, JL, DeVane, CL, Elkashef, A et al. Modafinil and cocaine interactions. Am. J. Drug Alcohol Abuse, 2006, 32, 577-87.
45. Dackis, CA, Kampman, KM, Lynch, KG, Pettinati, HM, O'Brien, CP. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology, 2005, 30, 205-211.
46. Anderson, AL, Reid, MS, Li, SH, Holmes, T, Shemanski, L et al. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend., 2009, 104, 133-9.
47. Rogawski, MA, Loscher, W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci, 2004, 5, 553-64.
48. Landmark, CJ. Targets for antiepileptic drugs in the synapse. Med. Sci. Monit., 2007, 13, RA1-7.
49. Dickenson, AH, Ghandehari, J. Anti-convulsants and anti-depressants. Handb. Exp. Pharmacol., 2007, 145-77.
50. 2+ influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices. Br. J. Pharmacol., 2000, 130, 900-6.
51. Shimoyama, M, Shimoyama, N, Hori, Y. Gabapentin affects glutamatergic excitatory neurotransmission in the rat dorsal horn. Pain, 2000, 85, 405-14.
52. +-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci. Lett., 2000, 280, 107-10.
53. Maneuf, YP, McKnight, AT. Block by gabapentin of the facilitation of glutamate release from rat trigeminal nucleus following activation of protein kinase C or adenylyl cyclase. Br. J. Pharmacol., 2001, 134, 237-40.
54. 3H]-glutamate from the caudal trigeminal nucleus of the streptozotocin-treated rat. Br. J. Pharmacol., 2004, 141, 574-9.
55. Cunningham, MO, Woodhall, GL, Thompson, SE, Dooley, DJ, Jones, RS. Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro. Eur. J. Neurosci., 2004, 20, 1566-76.
56. Coderre, TJ, Kumar, N, Lefebvre, CD, Yu, JS. A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. J. Neurochem., 2007, 100, 1289-99.
57. Bisaga, A, Aharonovich, E, Garawi, F, Levin, FR, Rubin, E et al. A randomized placebo-controlled trial of gabapentin for cocaine dependence. Drug Alcohol Depend., 2006, 81, 267-74.
58. Gonzalez, G, Desai, R, Sofuoglu, M, Poling, J, Oliveto, A et al. Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. Drug Alcohol Depend., 2007, 87, 1-9.
59. Raby, WN. Gabapentin therapy for cocaine cravings. Am. J. Psychiatry, 2000, 157, 2058-9.
60. Myrick, H, Henderson, S, Brady, KT, Malcolm, R. Gabapentin in the treatment of cocaine dependence: a case series. J. Clin. Psychiatry, 2001, 62, 19-23.
61. Raby, WN, Coomaraswamy, S. Gabapentin reduces cocaine use among
62. Berger, SP, Winhusen, TM, Somoza, EC, Harrer, JM, Mezinskis, JP et al. A medication screening trial evaluation of reserpine, gabapentin and lamotrigine pharmacotherapy of cocaine dependence. Addiction, 2005, 100 Suppl 1, 58-67.
63. Haney, M, Hart, C, Collins, ED, Foltin, RW. Smoked cocaine discrimination in humans: effects of gabapentin. Drug Alcohol Depend., 2005, 80, 53-61.
64. Leach, MJ, Marden, CM, Miller, AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia, 1986, 27, 490-7.
65. Lees, G, Leach, MJ. Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neurological cultures from rat cortex. Brain Res., 1993, 612, 190-9.
66. Teoh, H, Fowler, LJ, Bowery, NG. Effect of lamotrigine on the electrically-evoked release of endogenous amino acids from slices of dorsal horn of the rat spinal cord. Neuropharmacology, 1995, 34, 1273-8.
67. Waldmeier, PC, Baumann, PA, Wicki, P, Feldtrauer, JJ, Stierlin, C et al. Similar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. Neurology, 1995, 45, 1907-13.
68. Waldmeier, PC, Martin, P, Stocklin, K, Portet, C, Schmutz, M. Effect of carbamazepine, oxcarbazepine and lamotrigine on the increase in extracellular glutamate elicited by veratridine in rat cortex and striatum. Naunyn. Schmiedebergs Arch. Pharmacol., 1996, 354, 164-72.
69. Lingamaneni, R, Hemmings, HC, Jr. Effects of anticonvulsants on veratridine-and KCl-evoked glutamate release from rat cortical synaptosomes. Neurosci. Lett., 1999, 276, 127-30.
70. Cunningham, MO, Jones, RS. The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology, 2000, 39, 2139-46.
71. Wang, SJ, Sihra, TS, Gean, PW. Lamotrigine inhibition of glutamate release from isolated cerebrocortical nerve terminals (synaptosomes) by suppression of voltage-activated calcium channel activity. Neuroreport, 2001, 12, 2255-8.
72. Ahmad, S, Fowler, LJ, Whitton, PS. Effects of acute and chronic lamotrigine treatment on basal and stimulated extracellular amino acids in the hippocampus of freely moving rats. Brain Res., 2004, 1029, 41-7.
73. 3H]glutamate in hippocampal nerve endings. Neuropharmacology, 2007, 52, 598-605.
74. Margolin, A, Avants, SK, DePhilippis, D, Kosten, TR. A preliminary investigation of lamotrigine for cocaine abuse in HIV-seropositive patients. Am. J. Drug Alcohol Abuse, 1998, 24, 85-101.
75. Brown, ES, Nejtek, VA, Perantie, DC, Orsulak, PJ, Bobadilla, L. Lamotrigine in patients with bipolar disorder and cocaine dependence. J. Clin. Psychiatry, 2003, 64, 197-201.
76. Brown, ES, Perantie, DC, Dhanani, N, Beard, L, Orsulak, P et al. Lamotrigine for bipolar disorder and comorbid cocaine dependence: a replication and extension study. J. Affect. Disord., 2006, 93, 219-22.
77. Pavlovic, Z. Lamotrigine reduces craving and depressive symptoms in cocaine dependence. J. Neuropsychiatry Clin. Neurosci., 2011, 23, E32.
78. Winther, LC, Saleem, R, McCance-Katz, EF, Rosen, MI, Hameedi, FA et al. Effects of lamotrigine on behavioral and cardiovascular responses to cocaine in human subjects. Am. J. Drug Alcohol Abuse, 2000, 26, 47-59.
79. Gryder, DS, Rogawski, MA. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J. Neurosci., 2003, 23, 7069-74.
80. Kaminski, RM, Banerjee, M, Rogawski, MA. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology, 2004, 46, 1097-104.
81. Xi, ZX, Gardner, EL. Hypothesis-driven medication discovery for the treatment of psychostimulant addiction. Curr. Drug Abuse Rev., 2008, 1, 303-327.
82. Niehaus, JL, Cruz-Bermudez, ND, Kauer, JA. Plasticity of addiction: a mesolimbic dopamine short-circuit? Am. J. Addict., 2009, 18, 259-71.
83. Kampman, KM, Pettinati, H, Lynch, KG, Dackis, C, Sparkman, T et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend., 2004, 75, 233-40.
84. Reis, AD, Castro, LA, Faria, R, Laranjeira, R. Craving decrease with topiramate in outpatient treatment for cocaine dependence: an open label trial. Rev. Bras. Psiquiatr., 2008, 30, 132-5.
85. Lising-Enriquez, K, Blank, D, Cushing, SJ, Bacher, IC, George, TP. Treatment of co-morbid cocaine dependence in schizophrenia with topiramate. Schizophr. Res., 2010, 116, 97.
86. Minozzi, S, Amato, L, Davoli, M, Farrell, M, Lima Reisser, AA et al. Anticonvulsants for cocaine dependence. Cochrane Database Syst Rev, 2008, CD006754.
87. Shinn, AK, Greenfield, SF. Topiramate in the treatment of substance-related disorders: a critical review of the literature. J. Clin. Psychiatry, 2010, 71, 634-48.
88. Myers, KM, Carlezon, WA, Jr., Davis, M. Glutamate receptors in extinction and extinction-based therapies for psychiatric illness. Neuropsychopharmacology, 2011, 36, 274-293.
89. Myers, KM, Davis, M. Mechanisms of fear extinction. Mol. Psychiatry, 2007, 12, 120-150.
90. Davis, M, Ressler, K, Rothbaum, BO, Richardson, R. Effects of D-cycloserine on extinction: translation from preclinical to clinical work. Biol. Psychiatry, 2006, 60, 369-75.
91. Botreau, F, Paolone, G, Stewart, J. d-Cycloserine facilitates extinction of a cocaine-induced conditioned place preference. Behav. Brain Res., 2006, 172, 173-8.
92. Thanos, PK, Bermeo, C, Wang, GJ, Volkow, ND. D-Cycloserine accelerates the extinction of cocaine-induced conditioned place preference in C57BL/c mice. Behav. Brain Res., 2009, 199, 345-349.
93. Nic Dhonnchadha, BA, Szalay, JJ, Achat-Mendes, C, Platt, DM, Otto, MW et al. D-cycloserine deters reacquisition of cocaine self-administration by augmenting extinction learning. Neuropsychopharmacology, 2010, 35, 357-67.
94. Thanos, PK, Bermeo, C, Wang, GJ, Volkow, ND. D-cycloserine facilitates extinction of cocaine self-administration in rats. Synapse, 2011, 65, 938-44.
95. Torregrossa, MM, Sanchez, H, Taylor, JR. D-cycloserine reduces the context specificity of Pavlovian extinction of cocaine cues through actions in the nucleus accumbens. J. Neurosci., 2010, 30, 10526-33.
96. Price, KL, McRae-Clark, AL, Saladin, ME, Maria, MM, DeSantis, SM et al. D-cycloserine and cocaine cue reactivity: preliminary findings. Am. J. Drug Alcohol Abuse, 2009, 35, 434-8.
97. Friedmann, CTH, Davis, LJ, Ciccone, PE, Rubin, RT. Phase II double-blind controlled study of a new anxiolytic, fenobam (McN-3377) vs. placebo. Curr. Ther. Res., 1980, 27, 144-151.
98. Goldberg, ME, Salama, AI, Patel, JB, Malick, JB. Novel non-benzodiazepine anxiolytics. Neuropharmacology, 1983, 22, 1499-504.
99. Pecknold, JC, McClure, DJ, Appeltauer, L. Fenobam in anxious outpatients. Curr. Ther. Res., 1980, 27, 119-123.
100. Pecknold, JC, McClure, DJ, Appeltauer, L, Wrzesinski, L, Allan, T. Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. J. Clin. Psychopharmacol., 1982, 2, 129-33.
101. Itil, TM, Seaman, PA, Huque, M, Mukhopadhyay, S, Blasucci, D et al. The clinical and quantitative EEG effects and plasma levels of fenobam (McN-3377) in subjects with anxiety: an open rising dose tolerance and efficacy study. Curr. Ther. Res., 1978, 24, 708-724.
102. Montana, MC, Cavallone, LF, Stubbert, KK, Stefanescu, AD, Kharasch, ED et al. The metabotropic glutamate receptor subtype 5 antagonist fenobam is analgesic and has improved in vivo selectivity as compared to the prototypical antagonist 2-methyl-6-(phenylethynyl)-pyridine. J. Pharmacol. Exp. Ther., 2009, 330, 834-843.
103. Porter, RH, Jaeschke, G, Spooren, W, Ballard, T, Buettelmann, B et al. Fenobam: a clinically validated non-benzodiazepine anxiolytic is a potent, selective and non-competitive mGlu5 receptor antagonist with inverse agonist activity. J. Pharmacol. Exp. Ther., 2005, 315, 711-721.
104. Chiamulera, C, Epping-Jordan, MP, Zocchi, A, Marcon, C, Cottiny, C et al. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat. Neurosci., 2001, 4, 873-874.
105. Mcgeehan, AJ, Olive, MF. The mGluR5 antagonist MPEP reduces the conditioned rewarding effects of cocaine but not other drugs of abuse. Synapse, 2003, 47, 240-242.
106. Kenny, PJ, Boutrel, B, Gasparini, F, Koob, GF, Markou, A. Metabotropic glutamate 5 receptor blockade may attenuate cocaine self-administration by decreasing brain reward function in rats. Psychopharmacology, 2005, 179, 247-54.
107. Tessari, M, Pilla, M, Andreoli, M, Hutcheson, DM, Heidbreder, CA. Antagonism at metabotropic glutamate 5 receptors inhibits nicotine-and cocaine-taking behaviours and prevents nicotine-triggered relapse to nicotine-seeking. Eur. J. Pharmacol., 2004, 499, 121-33.
108. Mcgeehan, AJ, Janak, PH, Olive, MF. Effect of the mGluR5 antagonist 6-methyl-2-(phenylethynyl)pyridine (MPEP) on the acute locomotor stimulant properties of cocaine, d-amphetamine, and the dopamine reuptake inhibitor GBR12909 in mice. Psychopharmacology, 2004, 174, 266-273.
109. Lee, B, Platt, DM, Rowlett, JK, Adewale, AS, Spealman, RD. Attenuation of behavioral effects of cocaine by the metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)-pyridine in squirrel monkeys: comparison with dizocilpine. J. Pharmacol. Exp. Ther., 2005, 312, 1232-1240.
110. Herzig, V, Schmidt, WJ. Effects of MPEP on locomotion, sensitization and conditioned reward induced by cocaine or morphine. Neuropharmacology, 2004, 47, 973-984.
111. Paterson, NE, Markou, A. The metabotropic glutamate receptor 5 antagonist MPEP decreased break points for nicotine, cocaine and food in rats. Psychopharmacology, 2005, 179, 255-61.
112. Backstrom, P, Hyytia, P. Ionotropic and metabotropic glutamate receptor antagonism attenuates cue-induced cocaine seeking. Neuropsychopharmacology, 2006, 31, 778-786.
113. Backstrom, P, Hyytia, P. Involvement of AMPA/kainate, NMDA, and mGlu5 receptors in the nucleus accumbens core in cue-induced reinstatement of cocaine seeking in rats. Psychopharmacology, 2007, 192, 571-580.
114. Iso, Y, Grajkowska, E, Wroblewski, JT, Davis, J, Goeders, NE et al. Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic glutamate receptor subtype 5 antagonists; search for cocaine medications. J. Med. Chem., 2006, 49, 1080-1100.
115. Platt, DM, Rowlett, JK, Spealman, RD. Attenuation of cocaine self-administration in squirrel monkeys following repeated administration of the mGluR5 antagonist MPEP: comparison with dizocilpine. Psychopharmacology, 2008, 200, 167-76.
116. Martin-Fardon, R, Baptista, MA, Dayas, CV, Weiss, F. Dissociation of the effects of MTEP [3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]piperidine] on conditioned reinstatement and reinforcement: comparison between cocaine and a conventional reinforcer. J. Pharmacol. Exp. Ther., 2009, 329, 1084-90.
117. Veeneman, MM, Boleij, H, Broekhoven, MH, Snoeren, EM, Guitart, MM et al. Dissociable roles of mGlu5 and dopamine receptors in the rewarding and sensitizing properties of morphine and cocaine. Psychopharmacology, 2011, 214, 863-76.
118. Kotlinska, J, Bochenski, M. Pretreatment with group I metabotropic glutamate receptors antagonists attenuates lethality induced by acute cocaine overdose and expression of sensitization to hyperlocomotor effect of cocaine in mice. Neurotox. Res., 2011, 19, 23-30.
119. Keywood, C, Wakefield, M, Tack, J. A proof of concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-esophageal reflux disease. Gut, 2009, 58, 1192-9.
120. Zerbib, F, Bruley, dVS, Roman, S, Tutuian, R, Galmiche, JP et al. Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther., 2011, 33, 911-921.